 | | Vol. 14.03 – 24 January, 2023 |
| |
|
|
| Since proteasome inhibition is a common therapeutic strategy in multiple myeloma (MM), scientists investigated Rpn10, a subunit of the 19S proteasome unit, and found that it is highly expressed in MM cells versus normal plasma cells.
[Blood] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators isolated highly HSC-enriched CD34+CD38-CD45RA-CD90+CD49f+ cells from cord blood and adult bone marrow and mobilized peripheral blood samples obtained from normal humans spanning seven decades of age.
[Blood] |
|
|
|
| Researchers analyzed by differentiation tracing, using inducible Tie2– or Flt3-driven Cre recombinase, the roles of mouse HSCs and multipotent progenitors.
[Cell Stem Cell] |
|
|
|
| A series of zinc-finger protein repressors were designed to target within the human T-lymphotropic virus type I (HTLV-I) promoter that drove HTLV-I bZIP factor (HBZ) expression at highly conserved sites covering a wide range of HTLV-I genotypes.
[NAR Cancer] |
|
|
|
| Scientists used a DNA adductomic approach to characterize DNA adducts formed by reacting busulfan with calf-thymus DNA. Samples collected from 6 patients undergoing busulfan-based chemotherapy prior to allogeneic hematopoietic cell transplantation were analyzed for busulfan-derived DNA adduct detection.
[Molecular Therapy-Oncolytics] |
|
|
|
| Researchers investigated the impact of different protocols for surface coating of synthetic material and different anticoagulants on hemostasis and platelet activation in ex vivo human whole blood.
[Plos One] |
| |
|
|
| To evaluate the risks of clonal dominance and leukemogenesis, which have been reported in multiple gene therapy trials, investigators conducted a comprehensive DNA insertion site analysis of peripheral blood samples from the five patients in their gene therapy trial.
[Molecular Therapy-Methods & Clinical Development] |
|
|
|
| Scientists retrospectively analyzed data from a multi-center cohort of 1615 intensively treated AML patients and identified distinct co-mutational patterns for mutations of cohesin subunit SA-2.
[Blood Cancer Journal] |
|
|
|
| Researchers compared the genomic features and clinical outcomes between pediatric and young adult patients, and older adults with myeloproliferative neoplasms to gain insight into pathogenesis, disease prognosis, and management.
[British Journal Of Haematology] |
|  |
|
|
|
| The authors review the current knowledge of the genomic landscape of therapy-related myeloid neoplasms and discuss background knowledge of clonal hematopoiesis gained from studies of de novo myeloid neoplasms.
[Leukemia Research] |
|
|
|
|
| Priothera announced that the first patients have been enrolled in the pivotal MO-TRANS global Phase IIb/III study evaluating mocravimod in AML patients undergoing allogeneic hematopoietic cell transplant.
[Priothera ( Cision US Inc.)] |
|
|
|
|
| April 14 – 19, 2023
Orlando, Florida, United States |
|
|
|
|
|
| | Dresden University of Technology – Dresden, Germany |
|
|
|
| | Albert Einstein College of Medicine – New York, New York, United States |
|
|
|
| | Lund University – Lund, Sweden |
|
|
|
| | Hebrew University of Jerusalem – Jerusalem, Israel |
|
|
|
| | Upstate Medical University – Syracuse, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
